State of the art of genotypic HIV-1 drug resistance

Current Opinion in Infectious Diseases

Volumn 10, Issue 6, 1997, Pages 480-484

  Schuurman, Rob ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; RNA DIRECTED DNA POLYMERASE;

CELL CULTURE; DNA HYBRIDIZATION; DNA SEQUENCE; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ASSAY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; POINT MUTATION; POLYMERASE CHAIN REACTION; SHORT SURVEY; VIRUS GENE; VIRUS MUTANT; VIRUS RECOMBINATION; VIRUS TYPING;

EID: 0030776529     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199712000-00013     Document Type: Short Survey

References (27)

1. Schinazi RF, Larder BA, Mellors JW: Mutations in retroviral genes associated with drug resistance. Int Antivir News 1996, 4:95-107.
2. Lech WJ, Wang G, Yang YL, Chee Y, Dorman K, McCrae D, Lazzeroni JW, Erickson JW, Sinsheimer JS, Kaplan AH: In-vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996, 70:2038-2043.
3. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, Morris D, Hubbell E, Chee M, Gingeras T: Extensive polymorphism observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Med 1996, 2:753-759.
4. Lockhart D, Dong H, Byrne MC, Folletie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Dobayashi M, Horton H, Brown EL: Expression monitoring by hybridization to high density oligonucleotide arrays. Nature Biotechnol 1996,:1675-1680.
5. Kuritzkes DR, Quinn JB, Shugarts DL, Griffin A, Bakhtiari M, Poticha D, Eron JJ, Fallon MA, Rubin M: Drug resistance and virologic response to NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996, 10:975-981.
6. Leitner T, Halapi E, Scarlatti G, Rossi P, Albert J, Fenyo EM, Uhlén M: Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques 1993, 15:120-127.
7. Larder BA, Kellam P, Kemp SD: Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes AIDS 1991, 5:137-144.
8. de Jong MD, Schuurman R, Lange JMA, Boucher CAB: Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure. Antivir Ther 1996, 1:33-41.
9. Schmit JC, Ruiz L, Stuyver L, Van Laethem K, Vanderlinden I, De Clercq E, Clotet B, Vandamme AM: Comparison of the line probe HIV-1 reverse transcription assay, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. In Program and Abstracts of the 2nd National Conference on Human Retroviruses. 36 [Abstract]; 1997.
10. Najera I, Holguin A, Quinones-Mateu ME, Munoz-Fernandez MA, Najera R, Lopez Galindez C, Domingo E: Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995, 69:23-31.
11. Kaye S, Loveday C, Tedder RS: A mictrotitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J Med Virol 1992, 37:241-246.
12. Alexander MA, Winslow DL, Anton A, Logue K, Bacheler LT: Detection of HIV mutants resistant to protease inhibitors by solid-phase non-radioactive minisequencing. 2nd National Conference on Human Retroviruses. 117 [Abstract]; 1995.
13. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C et al.: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419.
14. Loveday C, Kaye S, Tenant Flowers M, Semple M, Ayliffe U, Weller IV, Tedder RS: HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 1995, 345:820-824.
15. de Jong MD, Veenstra J, Stilianakis NI, Schuurman R, Lange JMA, de Boer RJ, Boucher CAB: Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci USA 1996, 93:5501-5506.
16. Brun-Vézinet F, Boucher CAB, Loveday C, and the DELTA virology working group: HIV-1 viral load, phenotype and resistance in a subset of drug-native participants from the DELTA trial. submitted 1997.
17. Holodniy M, Mole L, Margolis D, Moss J, Dong H, Boyer E, Urdea M, Kolberg J, Eastman S: Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. J Virol 1995, 69:3510-3516.
18. Eastman PS, Boyer E, Mole L, Kolberg J, Urdea M, Holodniy M: Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance. J Clin Microbiol 1995, 33:2777-2780.
19. Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede C, Rimland D, Schinazi RF, Rossau R: Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcription gene. Antimicrob Agents Chemother 1997, 41:284-291.
20. Stuyver L, Wyseur A, Vanarnhem W, Hernandez F, Maertens G: Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996, 34:2259-2266.
21. Stuyver L, Wyseur A, Rombout A, Rimland D, Rossau R, Schinazi R: Line Probe Assay (LiPA) for HIV-1 RT: prevalence of drug-selected resistant isolates in a HIV-1 infected veterans affairs patient population. 4th Conference on Retroviruses and Oportunistic Infections. 182 [Abstract]; 1997.
22. Schuurman R, Tijnagel J, Bal E, Nijhuis M, Parker D, Boucher C: Detection of drug rersistance mutations in the HIV-1 RT gene using a line probe assay (LiPA). 4th Conference on Retroviruses and Opportunistic Infections. 181 [Abstract]; 1997.
23. Schuurman R: Diagnostic methods for HIV resistance [Abstract]. Int Antivir News 1997, 5:97-99.
24. Schuurman R, Graaf LD, Tijnagel J, Boucher C: Detection and quantification of nucleoside analogue resistance mutations using the HIV-1 reverse transcription line probe assay on longitudinal patient samples. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, Florida, USA. 34-35 [Abstract]; 1997.
25. Nijhuis M, Schuurman R, de Jong D, van Leeuwen R, Lange JMA, Danner SA, Keulen W, de Groot T, Boucher CAB: Lamivudine resistant HIV-1 variants (M184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis 1997, 176:398-405.
26. Tisdale M, Kemp SD, Parry NR, Larder BA: Rapid in-vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDO region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
27. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.